|Current News Articles
Lein closes first tranche of funding round
Lein closed the first tranche of its current funding round at the start of the summer with investment from a syndicate of investors including:Henley Business AngelsOIONVentureFounders.The second tranche of this round will close later in the year.
The funds raised are to be used to simultaneously provide working capital to underpin the commercial sales growth that the company is seeing and to support the development of the company’s own innovative products in the medical device space.
Lein achieves new ISO9001:2015 certification
Lein is pleased to announce that it has received further certification to the new internationally recognised ISO9001:2015 quality management standard. The independent assessment was conducted by the British Assessment Bureau and demonstrates Lein’s commitment to customer service and quality in delivery.
Sharon Branch, Lein’s Quality Manager, said “Moving forward and adapting our current quality management system to meeting the new 2015 regulations, just proves our ongoing drive to consistently provide products and services that not only meet customer requirements but also statutory and regularity requirements. We regularly demonstrate our need for seeking opportunities to enhance customer satisfaction because we understand how important it is for Lein to provide a robust quality system for our customers. We are extremely pleased that we have achieved ISO9001:2015 and we will continue to grow and improve on our methods and processes.”
Lein successfully completes KTP with Durham University
Lein is pleased to report that it has just successfully concluded its KTP (Knowledge Transfer Partnerships) project with Durham University. The project, to enhance Lein’s expertise in fluorescence confocal by developing pharmacokinetics instruments that can track drugs diffusing both in the eye and the skin, has proved to be a huge success.
The KTP associate, Dr. Kim Buttenschön took the core technology that she researched during her PHD and developed a fully engineered prototype that is now ready to be commercialised. This instrument will prove to be a key technology for both the pharmaceutical and cosmetic industries as they look for increased product development efficiencies.
Kim, who is moving back to her native Germany to manage government grant schemes, said “I have thoroughly enjoyed my three years at Lein. To be able to work at a rapidly growing, dynamic company like Lein has given me invaluable experience in both the technical and commercial aspects of the business. I would like to thank Lein, Durham University and the KTP for giving me this wonderful opportunity, which will stand me in good stead in the next stage of my career”.
Everyone at Lein wishes Kim all the very best as she continues, what we are sure will be, a very successful career. Dan Daly, CEO of Lein commented “We have worked with Kim for over 6 years, first during her PhD and subsequently during the KTP project. Lein’s growing commercial activities in fluorescence confocal metrology for disease diagnosis and treatment have been built on Kim’s excellent work.”